Robert Storey, EHRA 2019 – Patients with Atrial Fibrillation and Acute Coronary Syndrome

At the EHRA 2019 congress in Lisbon, Professor Robert Storey (Professor of Cardiology, Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK) joins us to discuss the latest research from the AUGUSTUS study and the challenges faced by patients with atrial fibrillation and acute coronary syndrome.

Filmed at EHRA 2019, Lisbon.

Speaker’s Disclosures: Dr Robert Storey has received consultancy fees, honoraria and/or research grants from AstraZeneca, Bayer, Bristol Myers, Haemonetics, Idorsia, Novartis, Squibb/Pfizer, PlaqueTec and Thromboserin.

Questions:

1. Please explain the challenges of managing antithrombotic therapy in patients with atrial fibrillation who have concomitant acute coronary syndrome or are undergoing percutaneous coronary intervention. (0:14)

2. What is the potential role of non-vitamin K antagonist oral anticoagulants (NOACs) in managing stroke risk in these patients? (1:31)

3. Are the AUGUSTUS findings consistent with other evidence examining the role of NOACs in managing stroke risk in patients with atrial fibrillation and acute coronary syndrome? (0:14)

touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.